<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prilocaine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prilocaine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prilocaine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11840" href="/d/html/11840.html" rel="external">see "Prilocaine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F213183"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Citanest Plain Dental [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868018"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>4% Citanest Plain Dental</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F213203"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F213185"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Dental anesthesia:</b> Infiltration or conduction block: Initial: 40 to 80 mg (1 to 2 mL) as a 4% solution. AAPD guidelines, 2009 maximum recommended dose within a 2-hour period:</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;70 kg: 6 mg/kg (400 mg)</p>
<p style="text-indent:-2em;margin-left:2em;">≥70 kg: 400 mg or 5 to 6 cartridges</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990012"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Undergoes renal metabolism; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50987281"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Undergoes hepatic metabolism; use with caution.</p></div>
<div class="block doe drugH1Div" id="F213186"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F213193"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="477be7c5-8e24-4519-a008-44919f938110">Dental anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dental anesthesia:</b> Infiltration or conduction block:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;10 years: Doses &gt;40 mg (1 mL) as a 4% solution per procedure rarely needed for procedures involving a single tooth, in a maxillary infiltration for 2 to 3 teeth, or for an entire quadrant with a mandibular block.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154937"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Undergoes renal metabolism; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51154938"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. Undergoes hepatic metabolism; use with caution.</p></div>
<div class="block adr drugH1Div" id="F213166"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Degree of adverse effects in the central nervous system and cardiovascular system are directly related to the blood levels of local anesthetic. The effects below are more likely to occur after systemic administration rather than infiltration.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrest, cardiovascular signs and symptoms (stimulation/depression), circulatory shock, edema, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Apprehension, confusion, convulsions, dizziness, drowsiness, euphoria, localized warm feeling, loss of consciousness, nervousness, numbness, oral paresthesia (may be persistent), sensation of cold, twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactoid reaction, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Respiratory arrest, respiratory depression</p></div>
<div class="block coi drugH1Div" id="F213173"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to local anesthetics of the amide type or any component of the formulation; patients with congenital or idiopathic methemoglobinemia</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Citanest Plain Dental: Severe shock or heart block; inflammation or sepsis in the region of proposed injection</p></div>
<div class="block war drugH1Div" id="F213163"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue). Use is contraindicated in patients with congenital or idiopathic methemoglobinemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease, severe shock, or heart block.</p>
<p style="text-indent:-2em;margin-left:4em;">• Familial malignant hyperthermia: Prilocaine may potentially trigger malignant hyperthermia; follow standard protocol for identification and treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; amide-type anesthetics are metabolized hepatically.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely-ill patients; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate dosing: To avoid serious adverse effects and high plasma concentrations, the lowest dosage resulting in effective anesthesia should be administered. Repeated doses may significantly increase blood concentrations of both the drug or its metabolites; tolerance to elevated blood concentrations varies with patient status. Reduced dosages, commensurate with age and physical condition, should be given to patients who are debilitated, elderly, acutely-ill, or pediatric.</p>
<p style="text-indent:-2em;margin-left:4em;">• Trained personnel: Dental practitioners using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>
<div class="block foc drugH1Div" id="F213170"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Citanest Plain Dental: 4% (1.8 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F213159"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F26597094"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Citanest Plain Dental Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% (per mL): $0.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868019"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4% Citanest Plain Dental: 4% (1.8 mL)</p></div>
<div class="block use drugH1Div" id="F14936535"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;">
<b>Local anesthesia:</b> Production of local anesthesia in dentistry by nerve block or infiltration techniques.</p></div>
<div class="block mst drugH1Div" id="F213208"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Prilocaine may be confused with Polocaine, PriLOSEC</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299942"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F213167"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F14079713"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have not been observed in animal reproduction studies. Prilocaine crosses the placenta.</p></div>
<div class="block brc drugH1Div" id="F213175"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if prilocaine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering prilocaine to nursing women.</p></div>
<div class="block pha drugH1Div" id="F213162"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.</p></div>
<div class="block phk drugH1Div" id="F213172"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Infiltration: &lt;2 minutes; Inferior alveolar nerve block: &lt;3 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Infiltration: Complete anesthesia for procedures lasting 20 minutes; Inferior alveolar nerve block: ~2.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 190 to 260 L; crosses blood-brain barrier </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 40% to 55% (alpha<sub>1</sub> acid glycoprotein) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily metabolized hepatically and to a lesser extent renally; prilocaine hydrolyzed by amidases to produce ortho-toluidine and N-propylalanine; these compounds may also undergo ring hydroxylation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1.6 hours; may be prolonged with hepatic or renal impairment</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (&lt;5% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F213176"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Citanest | Pricanest</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Pricanest</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Citanest</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Pricanest</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Association of Pediatric Dentists (AAPD), Council on Clinical Affairs. Guideline on use of local anesthesia for pediatric dental patients. 2009. Available at http://www.aapd.org/media/Policies_Guidelines/G_LocalAnesthesia.pdf.</div>
</li>
<li>
<div class="reference">
                  Citanest Plain (prilocaine hydrochloride injection, solution) [prescribing information]. York, PA: Dentsply Pharmaceutical; August 2020.</div>
</li>
<li>
<div class="reference">
                  Citanest Plain Dental (prilocaine) [product monograph]. Woodbridge, Ontario, Canada: Dentsply Canada Ltd; October 2015.</div>
</li>
<li>
<div class="reference">
                  Dentsply Prilocaine Hydrochloride Dental Injection (prilocaine) [product monograph]. Woodbridge, Ontario, Canada: Dentsply Canada Ltd; September 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12366885">
<a name="12366885"></a>Haas DA, “An Update on Local Anesthetics in Dentistry,” <i>J Can Dent Assoc</i>, 2002, 68(9):546-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/12366885/pubmed" id="12366885" target="_blank">12366885</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6355236">
<a name="6355236"></a>Jastak JT and Yagiela JA, “Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,” <i>J Am Dent Assoc</i>, 1983, 107(4):623-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/6355236/pubmed" id="6355236" target="_blank">6355236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8185087">
<a name="8185087"></a>MacKenzie TA and Young ER, “Local Anesthetic Update,” <i>Anesth Prog</i>, 1993, 40(2):29-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/8185087/pubmed" id="8185087" target="_blank">8185087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831923">
<a name="20831923"></a>Moore PA and Hersh EV, "Local Anesthetics: Pharmacology and Toxicity," <i>Dent Clin North Am</i>, 2010, 54(4):587-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/20831923/pubmed" id="20831923" target="_blank">20831923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12512665">
<a name="12512665"></a>Wahl MJ, Schmitt MM, Overton DA, et al, “Injection Pain of Bupivacaine With Epinephrine vs. Prilocaine Plain,” <i>J Am Dent Assoc</i>, 2002, 133(12):1652-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/12512665/pubmed" id="12512665" target="_blank">12512665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL, “Epinephrine Interactions With Beta-Blockers,” <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1819966">
<a name="1819966"></a>Yagiela JA, “Local Anesthetics,” <i>Anesth Prog</i>, 1991, 38(4-5):128-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prilocaine-drug-information/abstract-text/1819966/pubmed" id="1819966" target="_blank">1819966</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10228 Version 131.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
